Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | SMO | Q99835 | 7/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 8/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 8/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | LTC4S | Q16873 | 1/20 | 0.37 |
| ▸ | CDK9 | P50750 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9932304 | 0.95 | PDE10A (0.38) | PDE10ASMOSLC6A2SLC6A3HCRTR1 | |
| SCHEMBL9968356 | 0.85 | KDM4E (0.41) | SMO | |
| SCHEMBL9933199 | 0.84 | PTPN11 (0.44) | PDE10ASMO | |
| SCHEMBL9968340 | 0.84 | MEN1 (0.40) | SMO | |
| SCHEMBL9933062 | 0.82 | PDE2A (0.42) | SMO | |
| SCHEMBL9931789 | 0.81 | PTPN11 (0.43) | SMO | |
| SCHEMBL12841368 | 0.80 | MEN1 (0.34) | SMOCDK9 | |
| SCHEMBL9933101 | 0.79 | CYP2D6 (0.45) | SMO | |
| SCHEMBL9932531 | 0.78 | MEN1 (0.43) | SMO | |
| SCHEMBL9968319 | 0.78 | MEN1 (0.46) | SMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157471-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157471-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157471-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157471-A1 | BENZIMIDAZOLE DERIVATIVES | SMO, RB1, GLI1 | PDE10A 1879/4885SMO 1/4885SLC6A2 4539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.